How Is PML Diagnosed in Tysabri Patients?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational Exposure Concerns

If you or a loved one is on Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), understanding how doctors diagnose this condition is critical. The medical community has long studied the link between natalizumab and PML, building a knowledge base that now guides careful monitoring. This page explains the diagnostic process and what it means for patients.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a severe demyelinating disease that typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 found that PML can present with a range of clinical and laboratory characteristics, and survival varies according to the underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and to withhold Tysabri dosing immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML and Clinical Presentation

The mechanistic pathway linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in the brain but also impairs the normal immune response that controls JC virus reactivation. In immunocompromised individuals, JC virus can infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The presence of anti-JCV antibodies indicates prior exposure to the virus, and patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Longer treatment duration, especially beyond 2 years, further increases risk, as does prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between Tysabri exposure and documented harm from PML can vary. PML may develop after months to years of treatment, with risk increasing with cumulative exposure. The boxed warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Common symptoms of PML include progressive weakness on one side of the body, clumsiness, vision changes, changes in thinking, memory, and orientation, and personality changes. The FDA Adverse Event Reporting System (FAERS) data show that adverse events most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically confirm PML, they reflect the types of neurological symptoms that could be consistent with PML and underscore the importance of prompt evaluation.

Adequacy of Warnings and Legal Considerations

Adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The prescribing information includes a boxed warning that clearly states Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies specific risk factors: presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also instructs healthcare professionals to monitor patients and withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The restricted distribution program, TOUCH, is designed to ensure that prescribers, patients, and pharmacies are educated about the risks and that patients are monitored regularly. However, despite these warnings, PML continues to occur in Tysabri-treated patients, raising questions about whether the warnings are sufficient to prevent harm or whether additional measures are needed. Attorney-related considerations for affected patients are important. Patients who develop PML after Tysabri treatment may face severe disability or death. The boxed warning and the TOUCH program are intended to mitigate risk, but if a patient develops PML, they may consider legal action to seek compensation for medical expenses, lost income, pain and suffering, and other damages. An attorney can help evaluate whether the warnings provided were adequate and whether the healthcare provider followed appropriate monitoring and risk mitigation protocols. The timeline between exposure and documented harm is relevant to legal claims, as PML may develop after months to years of treatment, and the risk increases with longer duration of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who were not adequately informed of the risk or who were not monitored appropriately may have grounds for a claim. An attorney experienced in Tysabri PML cases can assist in gathering medical records, identifying expert witnesses, and navigating the legal process.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, as indicated by its boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What symptoms should Tysabri patients watch for that may indicate PML?

Symptoms include progressive weakness on one side of the body, clumsiness, vision changes, changes in thinking, memory, and orientation, and personality changes. Immediate medical evaluation is crucial if any such symptoms appear.

Can I file a lawsuit if I developed PML after taking Tysabri?

Yes, patients who develop PML may consider legal action to seek compensation for damages. An attorney can evaluate whether warnings were adequate and whether proper monitoring occurred. The boxed warning and TOUCH program are designed to mitigate risk, but failures may support a claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.